Vatine Gad D, Al-Ahmad Abraham, Barriga Bianca K, Svendsen Soshana, Salim Ariel, Garcia Leslie, Garcia Veronica J, Ho Ritchie, Yucer Nur, Qian Tongcheng, Lim Ryan G, Wu Jie, Thompson Leslie M, Spivia Weston R, Chen Zhaohui, Van Eyk Jennifer, Palecek Sean P, Refetoff Samuel, Shusta Eric V, Svendsen Clive N
The Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, WI 53706, USA; Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.
Cell Stem Cell. 2017 Jun 1;20(6):831-843.e5. doi: 10.1016/j.stem.2017.04.002. Epub 2017 May 16.
Inactivating mutations in the thyroid hormone (TH) transporter Monocarboxylate transporter 8 (MCT8) cause severe psychomotor retardation in children. Animal models do not reflect the biology of the human disease. Using patient-specific induced pluripotent stem cells (iPSCs), we generated MCT8-deficient neural cells that showed normal TH-dependent neuronal properties and maturation. However, the blood-brain barrier (BBB) controls TH entry into the brain, and reduced TH availability to neural cells could instead underlie the diseased phenotype. To test potential BBB involvement, we generated an iPSC-based BBB model of MCT8 deficiency, and we found that MCT8 was necessary for polarized influx of the active form of TH across the BBB. We also found that a candidate drug did not appreciably cross the mutant BBB. Our results therefore clarify the underlying physiological basis of this disorder, and they suggest that circumventing the diseased BBB to deliver active TH to the brain could be a viable therapeutic strategy.
甲状腺激素(TH)转运体单羧酸转运体8(MCT8)的失活突变会导致儿童严重的精神运动发育迟缓。动物模型无法反映人类疾病的生物学特性。利用患者特异性诱导多能干细胞(iPSC),我们生成了MCT8缺陷的神经细胞,这些细胞表现出正常的TH依赖神经元特性和成熟过程。然而,血脑屏障(BBB)控制着TH进入大脑,神经细胞TH可用性降低可能是疾病表型的基础。为了测试血脑屏障的潜在作用,我们构建了基于iPSC的MCT8缺陷血脑屏障模型,发现MCT8对于TH活性形式跨血脑屏障的极化内流是必需的。我们还发现一种候选药物不能有效穿过突变的血脑屏障。因此,我们的结果阐明了这种疾病的潜在生理基础,并表明绕过患病的血脑屏障将活性TH输送到大脑可能是一种可行的治疗策略。